Clinical evaluation of @entity14407 cream in cutaneous @entity364 : a comparison with XXXX cream.

@entity1 @entity5897 @entity137 @entity4013 @entity14407 @entity364 @entity9585
A randomized, double-blind, parallel-group, multi-centre clinical trial was undertaken in 60 @entity1 with @entity4013 or @entity9585 versicolor to compare topical 2% @entity14407 cream with topical 2% @entity5897 cream. Treatment, by twice-daily application, was for 4 weeks or until earlier complete resolution of disease. Assessment was by laboratory mycological investigation and regular clinical/symptomatic evaluation, both during and for 2 to 6 weeks after therapy. Fifty-three @entity1 satisfactorily completed the trial, 28 of whom received @entity14407 and 25 @entity5897 . The groups were adequately well-matched. All assessment criteria showed @entity14407 to be at least as efficacious as @entity5897 , with no statistically significant differences between the two treatments. A number of assessment criteria, however, did show trends in favour of @entity14407 . @entity14407 resulted in mycological findings becoming negative in 92%, i.e. all but 2 of 25 @entity1 , by the end of treatment and a similar proportion (91%, 21 of 23 @entity1 ) remained mycologically negative 2 to 4 weeks after the end of therapy. With @entity5897 , only 79% (19 of 24 @entity1 ) became mycologically negative during treatment and this figure decreased further to 74% (14 of 19 @entity1 ) after therapy. Essentially similar results were seen for clinical assessments of erythema, itching and desquamation, these features being significantly and progressively eliminated or improved by both treatments in high proportions of @entity1 during therapy, followed by little tendency to return after the cessation of therapy. Overall clinical assessments demonstrated statistically significant improvement during the second, third and fourth weeks of treatment with both drugs. Only 4 @entity1 (two with each treatment) were reported as showing clinical deterioration at any stage during the trial, in all cases after the end of therapy. There were no reports of local or systemic adverse reactions to either drug, and laboratory screening investigations failed to reveal any signs of @entity137 . These results indicate that a 4-week course of twice daily topical 2% @entity14407 cream is extremely well tolerated and is at least as efficacious as an equivalent regimen of 2% @entity5897 for the treatment of @entity4013 or @entity9585 versicolor. Trends in the results suggest that @entity14407 may prove to be more efficacious than @entity5897 , particularly in relation to elimination of laboratory evidence of persistent @entity364 , which could be reflected in a lower incidence of subsequent relapse of the disease.
